Conflict of interest: Nothing to report.
A Phase 2 study of bortezomib combined with either idarubicin/cytarabine or cytarabine/etoposide in children with relapsed, refractory or secondary acute myeloid leukemia: A report from the Children's Oncology Group
Version of Record online: 29 JUN 2014
© 2014 Wiley Periodicals, Inc.
Pediatric Blood & Cancer
Volume 61, Issue 10, pages 1754–1760, October 2014
How to Cite
Horton, T. M., Perentesis, J. P., Gamis, A. S., Alonzo, T. A., Gerbing, R. B., Ballard, J., Adlard, K., Howard, D. S., Smith, F. O., Jenkins, G., Kelder, A., Schuurhuis, G. J. and Moscow, J. A. (2014), A Phase 2 study of bortezomib combined with either idarubicin/cytarabine or cytarabine/etoposide in children with relapsed, refractory or secondary acute myeloid leukemia: A report from the Children's Oncology Group. Pediatr. Blood Cancer, 61: 1754–1760. doi: 10.1002/pbc.25117
Clinical Trial information: Identification number: NCT00666588. Trial Registry: clinicaltrials.gov
- Issue online: 19 AUG 2014
- Version of Record online: 29 JUN 2014
- Manuscript Accepted: 5 MAY 2014
- Manuscript Received: 10 MAR 2014
- Takeda/Millenium Pharmaceuticals
- National Cancer Insititute. Grant Numbers: K12CA90433-04, K23CA113337
- NCI Children's Oncology Group. Grant Number: U10CA098543
Additional Supporting Information may be found in the online version of this article.
Fig. S1. Overall survival of all eligible, evaluable patients in the AAML07P1 trial by treatment group. Arm A shown in red and Arm B shown in blue.
Table SI. Post-treatment LIC
Please note: Wiley Blackwell is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.